Essex Investment Management Co. LLC reduced its position in Illumina, Inc. (NASDAQ:ILMN) by 2.2% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,735 shares of the life sciences company’s stock after selling 132 shares during the period. Essex Investment Management Co. LLC’s holdings in Illumina were worth $1,745,000 at the end of the most recent quarter.
Other large investors have also recently added to or reduced their stakes in the company. Next Capital Management LLC bought a new stake in shares of Illumina in the 2nd quarter valued at about $25,000. Massey Quick Simon & CO. LLC boosted its stake in Illumina by 3,100.0% in the 3rd quarter. Massey Quick Simon & CO. LLC now owns 96 shares of the life sciences company’s stock worth $29,000 after purchasing an additional 93 shares in the last quarter. North Star Investment Management Corp. acquired a new stake in Illumina in the 3rd quarter worth approximately $31,000. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in Illumina in the 2nd quarter worth approximately $37,000. Finally, Winslow Evans & Crocker Inc. boosted its stake in Illumina by 90.9% in the 3rd quarter. Winslow Evans & Crocker Inc. now owns 126 shares of the life sciences company’s stock worth $40,000 after purchasing an additional 60 shares in the last quarter. Institutional investors and hedge funds own 90.97% of the company’s stock.
ILMN traded down $1.09 during trading on Thursday, reaching $311.50. 2,830 shares of the company’s stock were exchanged, compared to its average volume of 730,197. Illumina, Inc. has a 1 year low of $263.30 and a 1 year high of $380.76. The company has a debt-to-equity ratio of 0.42, a current ratio of 6.79 and a quick ratio of 6.10. The stock has a market capitalization of $45.43 billion, a P/E ratio of 54.66, a price-to-earnings-growth ratio of 3.08 and a beta of 1.07. The company’s fifty day simple moving average is $297.90 and its 200-day simple moving average is $312.88.
ILMN has been the subject of a number of recent analyst reports. Canaccord Genuity cut shares of Illumina from a “buy” rating to a “hold” rating and lowered their target price for the stock from $330.00 to $300.00 in a research note on Tuesday, July 30th. BidaskClub upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research note on Wednesday, October 16th. ValuEngine raised shares of Illumina from a “hold” rating to a “buy” rating in a research report on Thursday, September 12th. Piper Jaffray Companies set a $348.00 price target on shares of Illumina and gave the stock a “buy” rating in a research report on Friday, September 27th. Finally, Deutsche Bank reduced their price target on shares of Illumina from $290.00 to $280.00 and set a “hold” rating for the company in a research report on Friday, July 12th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and twelve have given a buy rating to the stock. Illumina presently has a consensus rating of “Buy” and a consensus target price of $330.92.
In other news, SVP Mostafa Ronaghi sold 4,000 shares of Illumina stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $310.93, for a total transaction of $1,243,720.00. Following the completion of the transaction, the senior vice president now directly owns 80,585 shares of the company’s stock, valued at approximately $25,056,294.05. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Oene Mark Van sold 625 shares of Illumina stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $304.84, for a total transaction of $190,525.00. Following the transaction, the senior vice president now directly owns 14,209 shares of the company’s stock, valued at $4,331,471.56. The disclosure for this sale can be found here. Insiders have sold a total of 37,799 shares of company stock valued at $11,117,580 over the last three months. 0.38% of the stock is currently owned by insiders.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Featured Story: Penny Stocks
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.